IM Cannabis FY22 Revenue From Continuing Operations Grows 60% To $54.3M

Comments
Loading...
Zinger Key Points
  • Gross profit from continuing operations for FY 2022 was CA$9.2 million, compared to CA$6.3 million in 2021, an increase of 46%.
  • Adjusted EBITDA loss from continuing operations in 2022 was CA$11.5 million, compared to an adjusted EBITDA loss of CA$14.3 million in 2021.
  • Discover Fast-Growing Stocks Every Month

IM Cannabis Corp. IMCC IMCC FY 2022 revenues from continuing operations were CA$54.3 million, an increase of 60% compared to CA$34.1 million in 2021.

Q4 Financial Highlights

  • Revenues from continuing operations for Q4 2022 were CA$14.5 million, compared to CA$9.9 million in Q4 2021, an increase of 46%.

  • Gross profit from continuing operations for Q4 2022 was CA$2.6 million, compared to CA$0.98 million in Q4 2021, an increase of 165%.

  • Gross Margin in Q4 2022 was 19%, compared to 11% in Q4 2021.

  • Adjusted EBITDA loss from continuing operations in Q4 2022 was CA$1.9 million, compared to an adjusted EBITDA loss of CA$9.0 million in Q4 2021.

  • Net loss from continuing operations in Q4 2022 was CA$9.7 million, compared to CA$8.4 million in Q4 2021.

  • Net loss from discontinued operations in Q4 2022 was CA$23.8 million, compared to CA$4.1 million in Q4 2021.

Full Year 2022 Financial Highlights

  • Gross profit from continuing operations for the year ended December 31, 2022 was CA$9.2 million, compared to CA$6.3 million in 2021, an increase of 46%.

  • Gross margin from continuing operations in 2022 was 21%, compared to 25% in 2021.

  • Adjusted EBITDA loss from continuing operations in 2022 was CA$11.5 million, compared to an adjusted EBITDA loss of CA$14.3 million in 2021.

  • Net loss from continuing operations in 2022 was CA$24.9 million, compared to CA$0.7 million in 2021.

  • Net loss from discontinued operations in 2022 was CA$166.4 million, compared to CA$17.9 million in 2021.

  • Cash and cash equivalents as of December 31, 2022 were CA$2.4 million, compared with CA$13.9 million in December 31, 2021.

  • Total assets as of December 31, 2022 were CA$60.7 million, compared to CA$287.4 million in December 31, 2021, a decrease of 79%. The decrease is mainly attributed to a goodwill impairment of CA$107.8 million relating to Trichome acquisition and the deconsolidation of Trichome groups assets of CA$54.7 million.

  • Liabilities as of December 31, 2022 were CA$36.9 million, compared to CA$82.4 in December 31, 2021, a decrease of approximately 55%.

"The fourth quarter marked another pivotal moment on our trajectory to growth and profitability," stated Oren Shuster, CEO of IMC. "By commencing our exit from Canada, and the restructuring initiatives announced a few weeks back, we will be able to better focus our resources on growth opportunities in Israel, Germany and elsewhere in Europe. We are determined to continue with our strategic plan by maximizing efficiencies to create a leaner and more flexible organization to better suit the current market environment and our short- to mid-term objectives. We will continue building on the increasing demand and positive momentum in Israel and Germany, supported by strategic alliances with Canadian suppliers and a highly skilled sourcing team, to cement our leadership position in the markets we operate in."

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Jeff W on Unsplash

Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.